The possible therapeutic effect of blocking this receptor has been recently reported by Yamamura and colleagues, who demonstrated that the proliferation and migration of human prostate cancer cells was impaired by the CasR antagonist calcilytics [100]. This evidence concerns the gene CASR and prostate cancer.